- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Dr. Wagaskar explains the obesity paradox in prostate cancer
Vinayak G. Wagaskar, MBBS, explains the “obesity paradox”—improved survival outcomes in patients with a high body mass index (BMI)—that has been observed in patients with genitourinary malignancies, including prostate cancer.
Wagaskar also highlights a study presented at the 2021 European Association of Urology Congress which reported evidence of the obesity paradox in patients with metastatic castration-resistant prostate cancer (mCRPC). Specifically, an analysis of nearly 1600 patients with mCRPC enrolled across three phase 3 trials showed that the overall survival rate at 36 months was about 30% in obese patients (BMI >30) compared with 20% in overweight (25< BMI <30) and normal weight (20< BMI <25) patients.
Wagaskar is an instructor of urology at Mount Sinai in New York City.
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.
